Assessment of cardiovascular disease-associated mortality risk among early-stage breast cancer patients
This is one of the first studies to identify an approximate mortality crossover point between CSM and BC-specific mortality at about 8 years (97 months) in women aged 70–85, providing a clinically relevant, exploratory time point for increased cardiovascular monitoring in this high-risk population.